On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...

Johnson & Johnson (J&J ... In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with major depressive disorder (who were ...

An Oakland High School student has been charged with a felony for reportedly bringing a loaded handgun to school, prompting a lockdown of the school on Friday, March 21. A former music producer ...

Payment options are available based on insurance coverage. The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in children aged 4 ...

Debra Rankin has dedicated her life to education, and she said the biggest honor is seeing kids become strong learners. The Colorado Rockies have been playing at Coors Field for 30 years. This ...

The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic reactions in patients who weigh between 15 and 30 kilograms, the company said on ...

FDA approves Neffy 1 mg for children aged 4+ weighing 15 to <30 kg for allergic reactions. Most insured patients can access Neffy for $25, while cash price is $199 for two doses. Feel unsure about ...

FDA approved Johnson & Johnson’s Tremfya as the first IL-23 inhibitor with both SC and IV induction options for Crohn’s disease. Tremfya sales reached $3.67 billion in 2024, marking a 17% year ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV ...